FI84833C - Foerfarande foer framstaellning av nya terapeutiskt anvaendbara n-glykosylamider n-glykosylkarbamider och n -glykosylkarbamater. - Google Patents

Foerfarande foer framstaellning av nya terapeutiskt anvaendbara n-glykosylamider n-glykosylkarbamider och n -glykosylkarbamater. Download PDF

Info

Publication number
FI84833C
FI84833C FI862619A FI862619A FI84833C FI 84833 C FI84833 C FI 84833C FI 862619 A FI862619 A FI 862619A FI 862619 A FI862619 A FI 862619A FI 84833 C FI84833 C FI 84833C
Authority
FI
Finland
Prior art keywords
deoxy
glucopyranosyl
acid amide
octadecyl
formula
Prior art date
Application number
FI862619A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI84833B (fi
FI862619A0 (fi
FI862619A (fi
Inventor
Arnold Paessens
Karl Georg Metzger
Oswald Lockhoff
Yutaka Hayauchi
Peter Stadler
Klaus Georg Stuenkel
Gert Strelssle
Volker Klimetzek
Hans-Joachim Zeller
Hein-Peter Kroll
Helmut Brunner
Klaus Schaller
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of FI862619A0 publication Critical patent/FI862619A0/fi
Publication of FI862619A publication Critical patent/FI862619A/fi
Publication of FI84833B publication Critical patent/FI84833B/fi
Application granted granted Critical
Publication of FI84833C publication Critical patent/FI84833C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06—Aminosugars
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cosmetics (AREA)
  • Seasonings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
FI862619A 1985-06-20 1986-06-18 Foerfarande foer framstaellning av nya terapeutiskt anvaendbara n-glykosylamider n-glykosylkarbamider och n -glykosylkarbamater. FI84833C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3521994 1985-06-20
DE19853521994 DE3521994A1 (de) 1985-06-20 1985-06-20 N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln

Publications (4)

Publication Number Publication Date
FI862619A0 FI862619A0 (fi) 1986-06-18
FI862619A FI862619A (fi) 1986-12-21
FI84833B FI84833B (fi) 1991-10-15
FI84833C true FI84833C (fi) 1992-01-27

Family

ID=6273684

Family Applications (1)

Application Number Title Priority Date Filing Date
FI862619A FI84833C (fi) 1985-06-20 1986-06-18 Foerfarande foer framstaellning av nya terapeutiskt anvaendbara n-glykosylamider n-glykosylkarbamider och n -glykosylkarbamater.

Country Status (21)

Country Link
US (1) US4855283A (de)
EP (1) EP0206037B1 (de)
JP (1) JPH07116207B2 (de)
KR (1) KR930011281B1 (de)
CN (1) CN86104185A (de)
AT (1) ATE71631T1 (de)
AU (1) AU564222B2 (de)
CA (1) CA1289952C (de)
CS (1) CS270209B2 (de)
DE (2) DE3521994A1 (de)
DK (1) DK287886A (de)
ES (2) ES8801769A1 (de)
FI (1) FI84833C (de)
GR (1) GR861574B (de)
HU (1) HU206123B (de)
IE (1) IE58918B1 (de)
IL (1) IL79126A (de)
NO (1) NO166002C (de)
PH (1) PH26775A (de)
PT (1) PT82796B (de)
ZA (1) ZA864571B (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3812681A1 (de) * 1988-04-16 1989-11-02 Bayer Ag Substituierte n-glycosylamide, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
US5977336A (en) * 1993-03-16 1999-11-02 St. Louis University High molecular weight surface proteins of non-typeable haemophilus
ATE154027T1 (de) * 1993-08-30 1997-06-15 Bayer Ag Glycosylamide von 2-aminoacylamino-2-desoxy- zuckern
CA2175332C (en) * 1993-11-08 2009-04-07 Sheena M. Loosmore Haemophilus transferrin receptor genes
US6361779B1 (en) 1993-11-08 2002-03-26 Aventis Pasteur Limited Transferrin receptor genes
US6764682B1 (en) * 1994-06-16 2004-07-20 Aventis Pasteur Limited Adjuvant compositions containing more than one adjuvant
US6335018B1 (en) * 1995-05-01 2002-01-01 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
WO1996034623A1 (en) 1995-05-04 1996-11-07 Connaught Laboratories Limited Acellular pertussis vaccines and methods of preparation thereof
US5827654A (en) * 1995-05-08 1998-10-27 University Of Toronto Basal body rod protein genes of campylobacter
US6251405B1 (en) 1995-06-07 2001-06-26 Connaught Laboratories, Inc. Immunological combination compositions and methods
US5780606A (en) * 1995-06-07 1998-07-14 Connaught Laboratories Limited Neisseria meningitidis capsular polysaccharide conjugates
US6290971B1 (en) * 1995-06-15 2001-09-18 Aventis Pasteur Limited Adjuvant compositions comprising a mineral salt and another immunostimulating compound
US6048539A (en) * 1995-11-02 2000-04-11 Connaught Laboratories Limited Lactoferrin receptor protein
FR2746643B1 (fr) * 1996-04-01 1998-06-12 Techni Pharma Nouvelles compositions laxatives et leur procede de fabrication
ATE339965T1 (de) 1996-07-02 2006-10-15 Aventis Pasteur Vielwertige dtp-polio-impfstoffe
US6042820A (en) 1996-12-20 2000-03-28 Connaught Laboratories Limited Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
FR2762787B1 (fr) * 1997-04-30 2000-10-06 Pasteur Merieux Serums Vacc Composition vaccinale anti-helicobacter comprenant un adjuvant de type th1
FR2762788B1 (fr) * 1997-04-30 2000-10-06 Pasteur Merieux Serums Vacc Composition vaccinale anti-helicobacter pour usage par voie systemique sous-diaphragmatique
WO1998048836A1 (fr) * 1997-04-30 1998-11-05 Merieux Oravax Composition vaccinale anti-helicobacter comprenant un adjuvant de type th1
US5977337A (en) 1997-06-03 1999-11-02 Connaught Laboratories Limited Lactoferrin receptor genes of Moraxella
US7459524B1 (en) 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
US7785609B1 (en) 1999-03-16 2010-08-31 Sanofi Pasteur Limited Recombinant Haemophilus influenzae adhesin proteins
US6335182B1 (en) 1999-03-16 2002-01-01 Aventis Pasteur Limited Recombinant Haemophilus influenzae adhesin proteins
US7241449B1 (en) 1999-04-12 2007-07-10 Aventis Pasteur Limited Transferrin receptor genes of moraxella
CA2721011A1 (en) 1999-10-22 2001-05-03 Aventis Pasteur Limited Modified gp100 and uses thereof
GB0000891D0 (en) * 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
DE60124899T2 (de) 2000-05-10 2007-08-16 Sanofi Pasteur Ltd., Toronto Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
AUPS143402A0 (en) * 2002-03-28 2002-05-09 Alchemia Pty Ltd Anomeric derivatives of monosaccharides
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
DE60334145D1 (de) * 2002-11-26 2010-10-21 Eurocine Vaccines Ab Neue adjuvant auf der basis von aminen
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
EP1633189B1 (de) 2003-05-19 2017-07-05 Prothena Biosciences Limited Verkürzte fragmente von alpha-synuklein bei lbd-krankheit
MX2007001679A (es) 2004-08-09 2007-05-23 Elan Pharm Inc Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
CA2634888C (en) 2006-01-26 2016-06-21 Pfizer Products Inc. Novel glycolipid adjuvant compositions
UA90569C2 (ru) * 2006-01-26 2010-05-11 Пфайзер Продактс Инк. Композиция гликолипидного адьюванта (варианты) и способ ее получения
PT2118300E (pt) 2007-02-23 2015-09-22 Univ California Prevenção e tratamento da doença sinucleinopática e amiloidogénica
CA2678963C (en) 2007-02-23 2018-05-01 Elan Pharmaceuticals, Inc. Prevention and treatment of synucleinopathic and amyloidogenic disease
GB2450088A (en) * 2007-06-11 2008-12-17 Diosamine Dev Corp Optionally modified monosaccharides with imine/iminium or glycosidic amine/ammonium group for use in modifying the level of cytokines & in therapy
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
SG186689A1 (en) 2007-12-28 2013-01-30 Univ Tennessee Res Foundation Treatment and prophylaxis of amyloidosis
EP2196196A1 (de) 2008-12-10 2010-06-16 Medipol S.A. Verbindung, Medikament, Impfstoff und Nanokapseln
GB201000196D0 (en) * 2010-01-07 2010-02-24 Galvez Julian M Novel combination
KR102085465B1 (ko) 2010-05-14 2020-03-05 박스알타 인코퍼레이티드 키메라 ｏｓｐａ 유전자, 단백질 및 이의 사용 방법
EP3682897A1 (de) 2012-07-27 2020-07-22 Baxalta GmbH Zusammensetzungen mit chimären ospa-molekülen und verfahren zu ihrer verwendung
CN104628802B (zh) * 2013-11-07 2017-01-18 北大方正集团有限公司 从发酵液中提取并纯化尼莫克汀的方法
US11191832B2 (en) 2013-11-19 2021-12-07 Prothena Biosciences Limited Monitoring immunotherapy of Lewy body disease from constipation symptoms
EP3028711A1 (de) * 2014-12-05 2016-06-08 Gubra ApS Molekülbausteine für die Zusammenfügung mit Kohlenhydratderivaten, Fettsäurerückständen und Peptiden
US10456459B2 (en) * 2015-07-20 2019-10-29 Zoetis Services Llc Liposomal adjuvant compositions
CA2992892C (en) * 2015-07-20 2019-12-31 Zoetis Services Llc Liposomal adjuvant compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3213650A1 (de) * 1982-04-14 1983-10-27 Bayer Ag, 5090 Leverkusen N-glycosylierte carbonsaeureamid-derivate, verfahren zu ihrer herstellung sowie ihre verwendung zur beeinflussung der koerpereigenen abwehr
DE3344257A1 (de) * 1983-12-07 1985-06-13 Bayer Ag, 5090 Leverkusen Substituierte o-acyl-glycosylamide, verfahren zu iherer herstellung sowie ihre verwendung

Also Published As

Publication number Publication date
CA1289952C (en) 1991-10-01
HU206123B (en) 1992-08-28
CN86104185A (zh) 1987-04-08
FI84833B (fi) 1991-10-15
DK287886A (da) 1986-12-21
JPH07116207B2 (ja) 1995-12-13
ES557729A0 (es) 1989-04-16
DE3521994A1 (de) 1987-01-02
US4855283A (en) 1989-08-08
IE58918B1 (en) 1993-12-01
ES8801769A1 (es) 1988-02-16
JPS61293991A (ja) 1986-12-24
FI862619A0 (fi) 1986-06-18
DE3683410D1 (de) 1992-02-27
CS451386A2 (en) 1989-10-13
EP0206037A3 (en) 1988-02-03
IL79126A0 (en) 1986-09-30
AU5897986A (en) 1986-12-24
ES8900231A1 (es) 1989-04-16
ES556287A0 (es) 1988-02-16
ZA864571B (en) 1987-02-25
PH26775A (en) 1992-10-13
NO862199L (no) 1986-12-22
KR870000354A (ko) 1987-02-18
GR861574B (en) 1986-10-17
KR930011281B1 (en) 1993-11-29
DK287886D0 (da) 1986-06-19
HUT41049A (en) 1987-03-30
IL79126A (en) 1991-09-16
ATE71631T1 (de) 1992-02-15
EP0206037B1 (de) 1992-01-15
FI862619A (fi) 1986-12-21
NO166002B (no) 1991-02-04
CS270209B2 (en) 1990-06-13
IE861636L (en) 1986-12-20
EP0206037A2 (de) 1986-12-30
NO166002C (no) 1991-05-15
AU564222B2 (en) 1987-08-06
PT82796A (en) 1986-07-01
PT82796B (pt) 1988-12-15
NO862199D0 (no) 1986-06-03

Similar Documents

Publication Publication Date Title
FI84833C (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara n-glykosylamider n-glykosylkarbamider och n -glykosylkarbamater.
CN106573962B (zh) 新颖的聚糖共轭物及其用途
Toyokuni et al. Synthetic carbohydrate vaccines: synthesis and immunogenicity of Tn antigen conjugates
FI64164B (fi) Foerfarande foer framstaellning av 2-(2-acylamino-2-desoxi-(d)-glukosyl-3-0)-alkankarboxylsyrapeptid-derivat
US4446128A (en) Antigen derivatives and processes for their preparation
IL132739A (en) Substances that affect the immune system and their supplements, which are aminoalkyl glucosamidide phosphate compounds that are converted by many nobles, vaccines and pharmaceuticals that contain them
IE51058B1 (en) Tetrapeptides and pentapeptides,their preparation and compositions containing them
FI72733B (fi) Foerfarande foer framstaellning av farmakologiskt verkande glukosderivat samt mellanprodukter anvaenda vid foerfarandet.
EP3389643B1 (de) Neuartige muramylpeptidderivatverbindung, synthese und verwendungen davon
US4461761A (en) Oligomers of compounds of the muramyl-peptide type and medicaments containing them
NO151201B (no) Fremgangsmaate for fremstilling av terapeutisk virksomme antigenderivater.
NZ251297A (en) Immunomodulating oligopeptides (2-5aa) possessing a long lipophilic alkyl chain and compositions thereof
EP3387005B1 (de) Neuartige muramylpeptidderivatverbindung, synthese und verwendungen davon
US4693998A (en) Novel compounds of the muramyl peptide
CA1321993C (en) Substituted n-glycosylamides, process for their preparation, and their use as medicaments
KR910008107B1 (ko) 무라밀디펩타이드 활성 에스테르 유도체의 제조방법
US4230696A (en) Polypeptides useful for the purpose of treating multiple sclerosis
Tomašić et al. Peptidoglycan monomer originating from Brevibacterium divaricatum—its metabolism and biological activities in the host
CA1262015A (en) Acylated sugar derivatives, processes for their manufacture, and their use
EP0173960B1 (de) Aktive Muramylpeptidester-Derivate
GB1584791A (en) Muromyl peptide immunological adjuvants
KR830002059B1 (ko) 멀아밀-펲타이드형태인 신규 화합물의 제조방법
Dmitriev et al. Glycopeptidolipids—a new class of artificial antigens with carbohydrate determinants. Synthesis of artificial antigen with type-specific oligosaccharide hapten from Neisseria meningitidis group B
IE49617B1 (en) Novel compounds of the muramyl-peptide type and medicaments containing them
Wu Modulators of Toll-like Receptors-4 and-2

Legal Events

Date Code Title Description
MM Patent lapsed
MM Patent lapsed

Owner name: BAYER AKTIENGESELLSCHAFT